Press Releases

Date Focus Highlight
June
28th,
2012
OneTRAC™ Launch “By combining the coverage breadth of OneArray® microarrays and the high-throughput, multiplex capabilities of TRAC, OneTRAC™ offers researchers in industry and academia an integrated approach towards identifying, selecting and validating a robust set of gene expression signatures.” Vivien Mak, Ph.D., Phalanx Biotech’s President, further supported the significance of the OneTRAC™ solution, “With continued interest among drug sponsors to supplement US regulatory submissions with toxicogenomic data, we believe the flexibility and scalability of OneTRAC™ will be well-received by customers investigating expression profiling at both the genome-wide and focused-gene levels.”
May
8th,
2012
CytoOneArray® Announced “Extensive testing from our CytoOneArray® manufacturing campaign demonstrates a quality product with high sensitivity, robustness, and reproducibility. We are extremely excited about offering our focused CMA at the time when cytogeneticists are adopting chromosomal microarray as a first-tier clinical diagnostic test.” said Shengwan Lee, Ph.D., President and CEO. “As the first in a series of CMA microarrays, Phalanx will continue to expand its line of clinical diagnostic products by leveraging its high performance microarray technology and innovative manufacturing processes.”
March
12th,
2012
microRNA V18 Launch "At Phalanx Biotech, we recognize the importance of providing our microarray customers with probe content that matches the latest database annotations. With the fourth update to our microRNA OneArray® product line and specialized protocols for FFPE, serum, urine, rice plant samples and high efficiency hybridization, our one-stop service facility from the original array provider, offer scientists the most comprehensive solution for microRNA expression profiling," said Shengwan Lee, Ph.D., President and CEO. "In combination with over 100% growth of our OneArray® microRNA business in 2011, we are extremely pleased with the adoption of our microarrays among the research community and anticipate an even greater growth rate in our microRNA business this year."
March
5th,
2012
Robust Revenue Growth in 2011 "PhalanxBio, Inc., a wholly-owned, US subsidiary of Phalanx Biotech Group, achieved record 2011 sales in its target markets of North America and Europe – growing revenues more than 20% year over year," announced Shengwan Lee, Ph.D., President and CEO. "Our growth in this highly competitive marketplace is a strong testament by our customers of the performance and value of our OneArray® microarray products and services. To underscore our commitment to delivering the highest quality products and services, I am also pleased to announce our recent ISO:9001:2008 and 13485:2003 certification – a validation of our adherence to the rigorous quality management systems at Phalanx Biotech."
August
24th,
2011
microRNA V17 Launch "This latest microRNA product release marks the third update to our microRNA product line, and features not only the most current annotation, but also a new hybridization chemistry enabling greater microarray signal intensities at reduced sample input," said Richard Su, Head of Product Development. "Furthermore, as our whole genome gene expression microarray product line expands, we anticipate a set of complementary microRNA microarrays to offer researchers the capability to conduct gene and microRNA expression profiling studies in parallel."
July
6th,
2011
Rice Microarray Launch "As the world's major food staple, rice has been one of the most studied plant genomes. Genomic tools for gene expression profiling and sequence analysis will enable researchers to develop rice strains with improved crop yield as well as tolerance against various environmental stresses," said Shengwan Lee, President and CEO. "As a strong proponent of agricultural research to improve global food supplies, we plan to develop expression microarrays for additional crops to allow researchers around the globe to benefit from affordable genomics screening assays."
March
16th,
2011
Rat Microarray Launch "Amidst an environment of budget constraints, the release of our high-quality and affordable rat microarray is timely for the rat model research community - particularly with increased efforts toward understanding the underlying mechanisms of neurological and inflammatory diseases," said Lester Lien, President, US Operations. "Furthermore, as the FDA starts requiring toxicogenomic data in new drug applications, expression profiling in rat models will be necessary for biomarker development and validation in the drug development process."